Toxicity testing of peptide for human use

Area of Science:

• Pharmacology
• Toxicology
• Biochemistry

Background:

• The safety evaluation of novel peptides requires standardized animal testing protocols, which are currently under discussion.
• Peptides, particularly those of human origin or with localized biological action, may pose risks when systemically administered at high concentrations.
• Synthetic peptide analogues can potentially be evaluated using standard toxicological methods for synthetic compounds.

Purpose of the Study:

• To address the ongoing dispute regarding the extent and design of animal testing for new peptides.
• To evaluate the risks associated with systematically administered peptides, especially those of human origin or with localized secretion.
• To propose current best practices for peptide toxicity testing.

Main Methods:

• Review of existing methodologies for animal testing of peptides.
• Consideration of subacute and prolonged toxicity studies in animal models.
• Evaluation of specific tests such as hypotensive effect in cats.
• Assessment of batch-to-batch consistency in peptide synthesis.

Main Results:

• Subacute or prolonged toxicity studies in animals are relevant for human-origin peptides to assess risks to distant organs.
• Synthetic peptide analogues may be tested similarly to other synthetic compounds.
• Improved synthesis and characterization methods could reduce batch variability in the future.

Conclusions:

• Current peptide toxicity testing should include hypotensive effect studies in cats.
• Subacute toxicity studies in animals are recommended for each batch of peptides prepared via solid-phase synthesis.
• Standardization of animal testing protocols for peptides is crucial for ensuring drug safety.